TY - JOUR
T1 - National survey of percutaneous coronary intervention during the COVID-19 pandemic in Japan
T2 - second report of the Japanese Association of Cardiovascular Intervention and Therapeutics
AU - Ishii, Hideki
AU - Amano, Tetsuya
AU - Kohsaka, Shun
AU - Morino, Yoshihiro
AU - Yokoi, Hiroyoshi
AU - Ikari, Yuji
N1 - Funding Information:
This work was supported by the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT; Japan) and the grants-in-aid of the 24th General Assembly of the Japanese Association of Medical Sciences.
Funding Information:
Hideki Ishii received lecture fees from Astellas Pharma, AstraZeneca, Bayer Pharmaceutical Co.Ltd., Chugai Pharma Inc., Daiichi-Sankyo, and MSD K. K. Tetsuya Amano received lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. Shun Kohsaka received investigator-initiated grant funding from Bayer and Daiichi Sankyo and received lecture fees from Bristol-Myers Squibb. Yoshihiro Morino received research grants and lecture fees from Boston Scientific Corporation, Terumo, Baier, Japan lifeline, and Daiichi-Sankyo, and received lecture fees from Kowa pharmaceutical and Amgen. Hiroyoshi Yokoi received lecture fees from Abbott Vascular Japan Co., Ltd., Amgen Astellas BioPharma, Astellas Pharma, Abbott Vascular Japan Co., Ltd., Bayer Pharmaceutical Co.Ltd., Boston Scientific Corporation, Daiichi Sankyo, HeartFlow Japan G.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Company, and Terumo Co., Ltd. Yuji Ikari received research grant from Boston Scientific and Bayer.
Publisher Copyright:
© 2021, Japanese Association of Cardiovascular Intervention and Therapeutics.
PY - 2022/4
Y1 - 2022/4
N2 - Healthcare systems worldwide have been overburdened by the coronavirus disease 2019 (COVID-19) outbreak. Accordingly, hospitals have had to implement strategies to profoundly reorganize activities, which have affected procedures such as primary percutaneous coronary interventions (PCIs). This study aimed to describe changes in PCI practices during the health emergency at the national level. The Japanese Association of Cardiovascular Intervention and Therapeutics performed provided serial surveys of institutions throughout Japan during the pandemic. The data obtained on December, 2020 and February 2021 (during the 2nd wave of pandemic) were compared with the data obtained on August 2020 (1st wave). Primary PCI for STEMI was performed as usual in 99.1%, 98.7%, and 97.5% of institutions in mid-August, mid-December, 2020 and mid-February, 2021, respectively. The COVID-19 screening tests rates in patients were significantly higher during the third wave than during the second wave (54.0% in mid-August, 2020 and 64.6% in mid-February, 2021, P = 0.002). In addition, hospitals reported that personal protective equipment was more available over time (66.4% in mid-August, 2020 and 83.8% in mid-February, 2021, P < 0.001). In conclusion, most institutions surveyed in Japan continued to perform primary PCI as usual for STEMI patients during the second and third waves of the COVID-19 pandemic. In addition, the COVID-19 screening tests were more frequently performed over time.
AB - Healthcare systems worldwide have been overburdened by the coronavirus disease 2019 (COVID-19) outbreak. Accordingly, hospitals have had to implement strategies to profoundly reorganize activities, which have affected procedures such as primary percutaneous coronary interventions (PCIs). This study aimed to describe changes in PCI practices during the health emergency at the national level. The Japanese Association of Cardiovascular Intervention and Therapeutics performed provided serial surveys of institutions throughout Japan during the pandemic. The data obtained on December, 2020 and February 2021 (during the 2nd wave of pandemic) were compared with the data obtained on August 2020 (1st wave). Primary PCI for STEMI was performed as usual in 99.1%, 98.7%, and 97.5% of institutions in mid-August, mid-December, 2020 and mid-February, 2021, respectively. The COVID-19 screening tests rates in patients were significantly higher during the third wave than during the second wave (54.0% in mid-August, 2020 and 64.6% in mid-February, 2021, P = 0.002). In addition, hospitals reported that personal protective equipment was more available over time (66.4% in mid-August, 2020 and 83.8% in mid-February, 2021, P < 0.001). In conclusion, most institutions surveyed in Japan continued to perform primary PCI as usual for STEMI patients during the second and third waves of the COVID-19 pandemic. In addition, the COVID-19 screening tests were more frequently performed over time.
KW - COVID-19
KW - Japan
KW - Percutaneous coronary intervention
KW - ST elevation myocardial infarction
KW - Survey
UR - http://www.scopus.com/inward/record.url?scp=85104828579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104828579&partnerID=8YFLogxK
U2 - 10.1007/s12928-021-00776-5
DO - 10.1007/s12928-021-00776-5
M3 - Article
C2 - 33864606
AN - SCOPUS:85104828579
SN - 1868-4300
VL - 37
SP - 264
EP - 268
JO - Cardiovascular Intervention and Therapeutics
JF - Cardiovascular Intervention and Therapeutics
IS - 2
ER -